Lite Strategy, INC. (LITS) — SEC Filings

Overview

Lite Strategy, INC. (LITS) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 30, 2025: Lite Strategy, Inc. (formerly MEI Pharma, Inc.) announced on December 23, 2025, the departure of Director Dr. Brian J. Fox and the appointment of Dr. David E. Johnson as a new director. The company also disclosed compensatory arrangements for certain officers, though specific details and dollar amou

Sentiment Summary

Across 35 filings, the sentiment breakdown is: 1 bullish, 1 bearish, 31 neutral, 2 mixed. The dominant filing sentiment for Lite Strategy, INC. is neutral.

Filing Type Overview

Lite Strategy, INC. (LITS) has filed 23 8-K, 1 8-K/A, 6 10-Q, 2 10-K, 1 DEF 14A, 2 SC 13G/A with the SEC between Jan 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (35)

• Lite Strategy Inc. Announces Director Changes — 8-K · Dec 30, 2025 Risk: medium
  Lite Strategy, Inc. (formerly MEI Pharma, Inc.) announced on December 23, 2025, the departure of Director Dr. Brian J. Fox and the appointment of Dr. David E. J
• Lite Strategy, Inc. Changes Certifying Accountant — 8-K · Dec 5, 2025 Risk: medium
  Lite Strategy, Inc. (formerly MEI Pharma, Inc.) filed an 8-K on December 5, 2025, reporting a change in its certifying accountant. The company, located at 9920
• Lite Strategy, Inc. Amends 8-K Filing — 8-K/A · Nov 20, 2025 Risk: medium
  Lite Strategy, Inc. filed an amendment (8-K/A) on November 20, 2025, to a report originally dated November 14, 2025. The filing pertains to the departure of dir
• Lite Strategy, Inc. Reports Board and Officer Changes — 8-K · Nov 18, 2025 Risk: medium
  Lite Strategy, Inc. announced on November 14, 2025, changes related to its board of directors and officers, including the departure of certain individuals and t
• Lite Strategy Pivots to Litecoin, Cuts Losses Amidst Treasury Shift — 10-Q · Nov 14, 2025 Risk: high
  Lite Strategy, Inc. (LITS) reported a net loss of $3.639 million for the three months ended September 30, 2025, a significant improvement from the $8.007 millio
• Lite Strategy Inc. Announces Director Changes and Officer Compensation — 8-K · Oct 30, 2025 Risk: low
  Lite Strategy, Inc. announced on October 24, 2025, the departure of Director Dr. David E. Johnson and the appointment of Dr. Jonathan M. Roth as a new director.
• Lite Strategy Pivots to Crypto with $100M Litecoin Treasury — 10-K · Sep 26, 2025 Risk: high
  Lite Strategy, Inc. (LITS) underwent a significant strategic shift in fiscal year 2025, transitioning from a pharmaceutical company to one focused on a Litecoin
• Lite Strategy, Inc. Reports Unregistered Equity Sales — 8-K · Sep 15, 2025 Risk: medium
  Lite Strategy, Inc. (formerly MEI Pharma, Inc.) filed an 8-K on September 15, 2025, reporting unregistered sales of equity securities on September 10, 2025. The
• MEI Pharma Files 8-K with Corporate Updates — 8-K · Sep 10, 2025 Risk: low
  MEI Pharma, Inc. filed an 8-K on September 10, 2025, reporting amendments to its articles of incorporation or bylaws, a Regulation FD disclosure, and financial
• MEI Pharma Enters Material Definitive Agreement — 8-K · Sep 4, 2025 Risk: medium
  MEI Pharma, Inc. announced on September 3, 2025, the entry into a material definitive agreement. This filing also indicates the creation of a direct financial o
• MEI Pharma Appoints New CFO and Directors — 8-K · Aug 6, 2025 Risk: medium
  MEI Pharma, Inc. announced on August 5, 2025, changes in its board and executive team. The company elected two new directors, Dr. David E. Johnson and Ms. Karen
• MEI Pharma Files 8-K with Financials and Other Events — 8-K · Aug 5, 2025 Risk: low
  MEI Pharma, Inc. filed an 8-K on August 5, 2025, reporting on various events. The filing includes information related to financial statements and exhibits, as w
• MEI Pharma Reports Unregistered Equity Sale — 8-K · Jul 30, 2025 Risk: medium
  MEI Pharma, Inc. announced on July 24, 2025, an unregistered sale of equity securities. The company, incorporated in Delaware, filed this Form 8-K to report thi
• MEI Pharma Announces Material Agreement Termination & Officer Changes — 8-K · Jul 22, 2025 Risk: medium
  MEI Pharma, Inc. announced on July 17, 2025, the termination of a material definitive agreement. The company also reported on unregistered sales of equity secur
• MEI Pharma Files Q3 2025 10-Q, Details Revenue and Agreements — 10-Q · May 13, 2025 Risk: medium
  MEI Pharma, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported revenue from collaboration agreements and contract with customers. Ke
• MEI Pharma Announces CMO Departure, Director Changes — 8-K · Mar 7, 2025 Risk: medium
  MEI Pharma, Inc. announced on March 3, 2025, the departure of Dr. Brian D. D. Smith from his role as Chief Medical Officer. The company also reported on the ele
• MEI Pharma Files Q2 2025 10-Q — 10-Q · Feb 12, 2025 Risk: medium
  MEI Pharma, Inc. filed its 10-Q for the period ending December 31, 2024, reporting on its financial performance for the second quarter. The company's fiscal yea
• MEI Pharma Files 8-K on Shareholder Vote Matters — 8-K · Jan 31, 2025 Risk: low
  MEI Pharma, Inc. filed an 8-K on January 31, 2025, reporting on matters submitted to a vote of security holders as of January 30, 2025. The filing details the c
• MEI Pharma Executive Compensation Details Revealed — DEF 14A · Dec 20, 2024 Risk: medium
  MEI Pharma, Inc. filed a DEF 14A on December 20, 2024, detailing executive compensation for the fiscal year ending June 30, 2024. The filing includes informatio
• MEI Pharma Files 8-K on Shareholder Nominations — 8-K · Nov 25, 2024 Risk: medium
  MEI Pharma, Inc. filed an 8-K on November 25, 2024, reporting on shareholder nominations pursuant to Exchange Act Rule 14a-11. The filing date for the report is
• MEI Pharma Files 8-K on Financials — 8-K · Nov 14, 2024 Risk: low
  MEI Pharma, Inc. filed an 8-K on November 14, 2024, reporting on its results of operations and financial condition as of November 12, 2024. The filing includes
• MEI Pharma Q1 2025 Update: Focus on Operations — 10-Q · Nov 12, 2024 Risk: medium
  MEI Pharma, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported revenue from collaboration agreements for the three months ended
• MEI Pharma Acquired by PharmaEssentia — 8-K · Oct 25, 2024 Risk: medium
  MEI Pharma, Inc. announced on October 22, 2024, the completion of its acquisition by PharmaEssentia Corporation. The transaction involved the acquisition of all
• MEI Pharma Files 2024 10-K, Details Partnerships and Assets — 10-K · Sep 19, 2024 Risk: medium
  MEI Pharma, Inc. filed its 10-K for the fiscal year ending June 30, 2024, detailing its operations and financial condition. The company's business includes agre
• MEI Pharma Announces Board Changes and New CMO — 8-K · Aug 2, 2024 Risk: medium
  MEI Pharma, Inc. announced on July 31, 2024, a series of significant corporate changes. These include the departure of Director Kevin R. Lind, the election of n
• MEI Pharma Files 8-K: Regulation FD & Exhibits — 8-K · Jul 30, 2024 Risk: low
  On July 30, 2024, MEI Pharma, Inc. filed an 8-K report to disclose information regarding a Regulation FD Disclosure and Financial Statements and Exhibits. The f
• PharmaEssentia to Acquire MEI Pharma for $416M — 8-K · Jul 22, 2024 Risk: medium
  MEI Pharma, Inc. announced on July 21, 2024, that it has entered into a definitive agreement to be acquired by PharmaEssentia Corporation for approximately $3.0
• MEI Pharma Appoints New Chief Medical Officer — 8-K · Jun 25, 2024 Risk: medium
  On June 18, 2024, MEI Pharma, Inc. announced the appointment of Dr. Brian A. Fox as Chief Medical Officer. Dr. Fox brings extensive experience in oncology drug
• MEI Pharma Files 8-K for Disclosure and Exhibits — 8-K · May 21, 2024 Risk: low
  MEI Pharma, Inc. filed an 8-K on May 21, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific
• MEI Pharma, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 9, 2024 Risk: medium
  MEI Pharma, Inc. (LITS) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. MEI Pharma, Inc. filed a 10-Q report for the quarter ended March 31, 2024.
• MEI Pharma Files Standard 8-K Report — 8-K · Feb 21, 2024 Risk: low
  MEI Pharma, Inc. filed an 8-K on February 21, 2024, reporting an event that occurred on February 20, 2024. The filing is a standard current report under Section
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 13, 2024
• MEI Pharma, Inc. Files 10-Q for Period Ending December 31, 2023 — 10-Q · Feb 13, 2024 Risk: medium
  MEI Pharma, Inc. (LITS) filed a Quarterly Report (10-Q) with the SEC on February 13, 2024. MEI Pharma, Inc. filed a 10-Q report for the period ending December 3
• MEI Pharma 8-K: Officer/Director Changes, Comp Arrangements — 8-K · Jan 17, 2024
  MEI Pharma, Inc. filed an 8-K on January 17, 2024, reporting an event that occurred on January 16, 2024, related to changes in its directors or officers and the

Risk Profile

Risk Assessment: Of LITS's 32 recent filings, 2 were flagged as high-risk, 22 as medium-risk, and 8 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Lite Strategy, INC.'s most recent 10-Q filing (Nov 14, 2025):

• Revenue: $0
• Net Income: -$3.639M
• EPS: -$0.12
• Debt-to-Equity: 0.01
• Cash Position: $10.113M
• Operating Margin: N/A
• Total Assets: $113.337M
• Total Debt: $1.068M

Key Executives

• Dr. Brian J. Fox
• Dr. David E. Johnson
• Dr. Jonathan M. Roth
• David M. Urso
• Richard Ghalie, M.D.
• Justin J. File
• Frederick W. Driscoll
• Ms. Karen L. Smith
• Mr. Michael T. Kelly
• Dr. Brian D. D. Smith
• David Urso
• Daniel Gold
• Kevin R. Lind
• Dr. David M. Erbe
• Dr. David J. Earp

Industry Context

The digital asset industry is characterized by rapid innovation, high volatility, and an evolving regulatory landscape. Companies are increasingly exploring the use of cryptocurrencies like Litecoin for treasury management and as a store of value. However, this sector faces significant competition from established financial institutions and numerous emerging blockchain-based ventures.

Top Tags

10-Q (5) · corporate-governance (4) · financials (4) · compensation (3) · equity-sale (3) · 8-K (3) · disclosure (3) · executive-appointment (3) · director-change (2) · officer-compensation (2)

Key Numbers

• Net Loss: $3.639M — Reduced from $8.007M in Q3 2024, indicating improved financial performance post-pivot.
• Digital Assets: $99.369M — New asset class, representing the company's strategic shift to holding Litecoin as a primary reserve.
• Cash and Cash Equivalents: $10.113M — Decreased from $18.011M at June 30, 2025, largely due to the purchase of digital assets.
• PIPE Offering: $100.0M — Proceeds used to fund the acquisition of Litecoin, signaling a major capital raise for the new strategy.
• Share Repurchase Program: $25.0M — Authorized in October 2025, indicating management's confidence and potential for shareholder returns.
• Common Shares Issued: 35,655 — Increased significantly from 6,663 at June 30, 2025, due to the PIPE offering and warrant exercises.
• Accumulated Deficit: $407.8M — Reflects historical losses since inception, highlighting the need for the new strategy to generate value.
• Change in fair value of digital assets (in thousands): 631 — First-time reporting of gains/losses from digital assets, reflecting the new business model.
• Total Operating Expenses: $3.739M — Significantly reduced from $8.352M in Q3 2024, contributing to the lower net loss.
• Net Loss Per Share: $0.12 — Improved from $1.20 in Q3 2024, despite increased share count, due to lower net loss.
• PIPE proceeds: $100.0 million — fully deployed into Litecoin Treasury Strategy in August 2025
• shares of common stock issued: 23,216,898 — part of the July 2025 PIPE at $3.42 per share
• pre-funded warrants issued: 6,022,869 — part of the July 2025 PIPE at $3.4199 per warrant
• market value of non-affiliate common equity: $12.0 million — as of December 31, 2024
• shares of common stock outstanding: 35,655,155 — as of September 23, 2025

Related Companies

LIT · LTC-USD · LTC · MEIP · KYC · PRPH

Frequently Asked Questions